4-aminopyridine for Skin Wound Healing
John Elfar
150 participants
Sep 1, 2025
INTERVENTIONAL
Conditions
Summary
Many patients suffer from chronic non-healing wounds as well as acute wounds. There is a need to develop treatments to accelerate and improve healing of chronic and acute wounds. More research is needed to evaluate the role of 4-aminopyridine (4-AP), a promising new agent with an excellent safety profile, on wound healing. The investigational treatment will be used to evaluate the role of (4-AP) on the treatment of wounds to accelerate wound healing in healthy adults. The purpose of this study is to evaluate the role of 4-AP on the treatment of wounds to accelerate healing. The investigational treatment will be used to test the hypothesis that 4-AP can speed wound healing.
Eligibility
Inclusion Criteria6
- Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm.
- Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination.
- Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention).
- Adults subject aged 18-70
- Ability to give written informed consent.
- Capable of safely coming in for follow up visits on all scheduled appointments.
Exclusion Criteria15
- History of multiple sclerosis, stroke or any other diagnosed neurological disorder
- History of hypersensitivity to AMPYRA® or 4-aminopyridine
- Current use of aminopyridine medications, including other compounded 4-AP
- Suspected renal impairment based on the Choyke questionnaire.
- History of difficult compliance with timely follow up
- Patients outside the age range
- Unable to provide informed consent.
- Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity).
- Patients with a concomitant traumatic brain injury.
- Patients unable to communicate.
- Patients unwilling to complete the study requirements.
- Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine.
- Pregnancy, breastfeeding or incarcerated individuals.
- Non-English speaking
- Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Active study drug
Placebo comparator
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06333171